What is Yumanity Therapeutics Financial Strength?
Yumanity Therapeutics has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Yumanity Therapeutics did not have earnings to cover the interest expense.
Yumanity Therapeutics's debt to revenue ratio for the quarter that ended in Sep. 2022 was 0.04.
As of today, Yumanity Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Yumanity Therapeutics's Financial Strength
For the Biotechnology subindustry, Yumanity Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yumanity Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Yumanity Therapeutics's Financial Strength falls into.
Yumanity Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Yumanity Therapeutics's Interest Expense for the
months ended in Sep. 2022 was $-0.00 Mil. Its Operating Income for the
months ended in Sep. 2022 was $-3.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil.
Yumanity Therapeutics's Interest Coverage for the quarter that ended in Sep. 2022 is
| Yumanity Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Yumanity Therapeutics's Debt to Revenue Ratio for the quarter that ended in Sep. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Yumanity Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yumanity Therapeutics (Yumanity Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Executives
| Shawn Iadonato |
director, officer: Chief Executive Officer |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Craig W. Philips |
officer: President |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Marion R Foote |
director |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Raymond J. Bartoszek |
director |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Keith Baker |
officer: Chief Financial Officer |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Pauline Kenny |
officer: General Counsel |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Thierry Guillaudeux |
officer: Chief Scientific Officer |
C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109 |
| Richard Peters |
director, officer: President & CEO |
MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
| Devin Whittemore Smith |
officer: SVP and General Counsel |
C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451 |
| Marie Epstein |
officer: Principal Accounting Officer |
C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135 |
| Michael D Wyzga |
officer: See Remarks |
C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135 |
| Paulash Mohsen |
officer: Chief Business Officer |
C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135 |
| Kimberlee C Drapkin |
director |
PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Ajay Verma |
officer: EVP, Head of R&D |
C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
| N Anthony Coles |
director, officer: Executive Chair |
MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Yumanity Therapeutics (Yumanity Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMTX has been successfully added to your